Objective: To investigate the effect of antioxidant supplementation on viral load and the antioxidantareactive oxygen species system in people with HIV. Design: Single centre, prospective, dose comparison study. Setting: Outpatient clinic specializing in HIV care. Subjects: Sixty-six participants were sequentially recruited by advertisement, and 48 subjects completed the study. Interventions: A recommended dose antioxidant regimen (5450 IU vitamin A as b-carotene, 250 mg vitamin C, 100 IU vitamin E, 100 mg selenium, 50 mg coenzyme Q10) or a high-dose antioxidant regimen (21 800 IU vitamin A as b-carotene, 1000 mg vitamin C, 400 IU vitamin E, 200 mg selenium, 200 mg coenzyme Q10) for a 12 week period. Results: Using repeated measures analysis of variance, the changes over treatment time were signi®cant for selenium, glutathione, glutathione peroxidase and lipid peroxides (P`0.03). Changes in allantoin, uric acid and viral load were not signi®cant (Pb0.05). The main effects for group and the interaction effects were not signi®cant for any of the parameters measured (P ! 0.05).
Introduction
Vitamin and mineral supplement usage is common in the HIV positive population in Australia and most Western countries. Morgan-Jones recently surveyed 150 (96% male) HIV positive people in three treatment centres in Sydney in which 53% used vitaminamineral supplements, predominantly multimicronutrient preparations (MorganJones 1998) . This compares with only 15.4% in the general Australian male population (McLennan & Podger, 1997) . Mean weekly expenditure, in the HIV positive population, on micronutrient supplements was A$7aweek, representing 9% of the mean expenditure on food and a substantial ®nancial load in a population where 55% were receiving a pension and a further 12% worked only part-time (MorganJones, 1998) .
Commonly in clinical practice and in published studies (Morgan-Jones, 1998) , patients attributed their use of supplements to desiring`to help ®ght the virus'. Rarely did a patient report supplement use from a belief that their diet was inadequate but instead they perceived the supplements were therapeutic in reducing their viral quantity and improving immune functioning (Morgan-Jones, 1998) . This belief has some scienti®c merit. It has been proposed that oxidative stress induced by reactive oxygen species (ROS) may play a role in the stimulation of HIV viral replication, speci®cally by activating the nuclear factor (NF)-KB (Duh et al, 1989) , which is thought to be necessary for HIV replication (Nabel & Baltimore, 1987) . ROS have been implicated in the development of immunode®ciency (Wong et al, 1991) and oxidative stress has also been causally linked to AIDS dementia complex (Bjugstad et al, 1998; Vincent et al, 1999) .
Previous research has shown that antioxidant defences including vitamin E, vitamin C, selenium, glutathione and co enzyme Q10 are compromised in HIV-positive subjects when compared with controls (Allard et al, 1998b; Folkers et al, 1988; Skurnick et al, 1996) . Oxidative stress has also been shown to be greater in HIV positive subjects when compared with controls (Allard et al, 1998b) .
In vitro, antioxidants have been shown to inhibit HIV transcription by suppressing NF-KB (Kalebic et al, 1991; Raju et al, 1994; Roederer et al, 1999) , to improve immune functioning by restoring lymphocyte proliferation (Cayota et al, 1996) and to reduce neurotoxicity risk, which may be useful in treating dementia (Foga et al, 1997) . Results of prospective antioxidant supplementation in vivo have been con¯icting. However comparisons are confounded by the use of different antioxidant supplement regimens and different methodologies to assess change.
Presently, in clinical practice, dietitians follow the guidelines of Galvin (1992) and Coodley et al (1993) , who recommend daily supplementation with a multivitamin and mineral preparation containing at least 100% of the Recommended Daily Allowance (RDA) but discourage megadosing (b10 times the RDA) (Food and Nutrition Board, 1989) . The aims of this study were ®rstly to examine baseline levels of oxidative stress and determine if any relationships exist between markers of oxidative stress and markers of HIV disease progression, and secondly to determine if multiple antioxidant supplementation has an effect on viral load or the reactive oxygen speciesaantioxidant system markers in people with HIVaAIDS. Thirdly and more speci®cally to determine if a recommended dose regimen differed from a high-dose regimen in any effect on viral load and oxidative stress markers.
Design and study description
This study was approved by the South Eastern Sydney Area Health Service Research Ethics Committee Ð Eastern Section. All patients enrolling in the study completed written informed consent.
Inclusion criteria for the study required subjects to be HIV positive and not taking multivitamin/mineral supplements for at least 4 weeks prior to the baseline visit. Participants had to be clinically stable with no active opportunistic infections for at least 6 weeks and had to be willing to complete the food diaries. Antiretroviral therapy, if used, had to be unchanged for the 6 weeks prior to study entry. Participants were not excluded if they smoked as this was designed as a clinical outcomes study assessing current practice, and we wished to assess antioxidant supplementation in a routine clinical population. Smoking may result in increased oxidative stress (Morrow et al, 1995) , however research is con¯icting (Cross et al, 1998) . Nor were participants excluded if they had hyperlipidaemia, which may correlate with increased lipid peroxidation (Bonithon-Kopp et al, 1997) . Measures used in this study had to be robust enough to detect changes in a standard clinical setting.
Participants were recruited sequentially into the low-dose (group one) and high-dose (group two) groups. At baseline participants were strati®ed into three different groups based on viral load and use of antiretroviral therapy. This strati®cation was used to ensure the sample preferentially recruited participants with a detectable viral load and that both those taking and not taking antiretroviral therapy were included. In addition the strati®cation was designed to eliminate potential baseline differences between the highand low-dose groups. Participants were divided into those: (A) not taking antiretroviral therapy with a detectable viral load (b400 copiesaml); (B) taking antiretroviral therapy with a detectable viral load (b400 copiesaml); and (C) taking antiretroviral therapy with an undetectable viral load (`400 copiesaml).
The ®rst 10 patients (group one) recruited into each of the three groups received the`recommended' dose orally on a daily basis. The remaining participants (group two) recruited in each arm received a`high' dose orally on a daily basis. Table 1 shows the dose of micronutrients received in the two different regimens. All supplements were provided free of charge to participants.
Procedures

Dietary intake
Participants were advised to maintain their current dietary intake throughout the study period in order to prevent Dietary intake assessment was conducted using a 4 day food diary prior to commencing the study and again in the ®nal month of the study.
Serum measures
Venous blood was collected for analysis after an overnight fast, between 08 00 and 10 30 h. Lithium heparin and potassium EDTA vacutainers were used for blood collection. Samples were then promptly transported to the laboratory, protected from light. An aliquot of whole blood was taken prior to centrifugation at 1500 g for 10 min and separation of plasma.
Reduced glutathione. An aliquot of whole blood EDTA was deproteinized immediately with metaphosphoric acid and the protein-free supernatant was kept at À70 C until analysis. Reduced glutathione levels were determined using reverse-phase high performance liquid chromatography (Shimadzu LC-10AD HPLC system) with¯ourometric detection (Shimadzu RF-551 spectro¯ourometer). An Altech Altima C 18 , 5 m, 250 Â 4.6 mm column was used with a phosphate bufferaacetonitrile mobile phase pH 3.2 at a¯ow rate of 1.8 mLamin, after derivatization with ammonium 7-¯ourobenzo-2-oxa-1,3-diazole-4-sulphonate (SBD-F).
Glutathione peroxidase. Glutathione peroxidase (GPX) activity of haemolysate was determined with Ransel kit (R5505, Randox Labs, Crumlin, North Ireland) using a Cobas Fara centrifugal analyser. This assay, based on the method of Paglia and Valentine (1967) , requires cumene hydroperoxide as a substrate. The ®nal concentrations of reagents in the assay were those recommended by the manufacturers. The sample volume was 285 ml. Absorbance was monitored at 340 nm for 3 min.
Lipid peroxides. A plasma aliquot was stored at À70 C for analysis by the method of Young and Trimble (1991) based on the formation of a malondialdehyde ± thiobarbituric acid (MDA-TBA) adduct. Malondialdehyde was used as the standard and the MDA-TBA adduct was quanti®ed by reverse-phase HPLC with¯ourescence detection at 553 nm (Shimadzu RF-551 spectro¯ourometric detector). A mobile phase phosphate bufferamethanolaacetonitrile, pH 6.5, was used with an Alltech Alltima TM C 18 , 4.6 Â 250 mm column.
Allantoin and uric acid. Allantoin and uric acid were measured using a method previously described (Lux et al, 1992) . Brie¯y plasma ultra®ltrate was obtained with Millipore Ultrafree-MC ®lter units with a cutoff at a molecular weight of 10 000. The ultra®ltrate was then stored at À20 C until analysis. Plasma ultra®ltrate was injected into a reverse-phase (C 18 ) HPLC column (Alltech Alltima TM 4.6 Â 250 mm) and the uric acid and allantoin were separated by isocratic elution using a mobile phase consisting of 5 mM phosphate buffer pH 3.1 and an ion pairing reagent (5 mM 1-Heptanesulfonic acid). The eluate was monitored by a UV detector (Shimadzu SPD-10A UV ± VIS) at 210 nm.
Selenium. Selenium levels were determined in plasma by a hydride generation atomic absorption (Varian Spectra-640Z, Varian, Australia). Viral load. Viral load was determined using Roche Amplicor monitor assay PCR kits with a lower limit of detection of 400 copiesaml.
Data analysis
Data were analysed using the SPSS statistical package (SPSS for Windows Version 6.1.3 (5a12a95) SPSS Inc., Chicago, Il, USA). Data are presented as mean AE standard deviation unless indicated. Chi square analysis was used to assess the signi®cance of differences between dichotomous variables. Differences between groups at baseline were analysed using the independent samples t-test or one-way analysis of variance with post hoc analysis using the Tukey HSD test. Changes in dietary parameters were measured using the Wilcoxon matched paired test for absolute amounts and paired t-tests for the percentage of the RDA. Changes in serum parameters were analysed using split plot repeated measures analysis of variance (Coakes & Steed, 1996) with change over treatment time as the within-subject effect and dose (group one or group two) as the betweensubject effect. Where there were baseline differences (P`0.05) between groups one and two, the baseline level was used as a covariate in the repeated measures analysis. Correlations were performed using Pearson's correlation coef®cient. Partial correlations were also performed when indicated.
Results
Sixty-six male participants entered the study between April 1998 and July 1999. Participants were recruited through outpatient clinics at the Albion Street Centre and through advertisement in the local gay press. Forty-eight participants completed the study. Two participants in group two withdrew from the study due to gastrointestinal discomfort. Other known reasons for study termination included changes in antiretroviral therapies (n 2) and dif®culties with attending appointment due to the limited serum collection times. Only the results of study completers are used for statistical purposes. Baseline characteristics are outlined in Table 2 .
Concurrent antiretroviral therapy
The number of participants entering and completing the study for each strati®cation arm and dose is shown in Table  3 . Using w 2 analysis the differences between those entering (P 0.623) or the number completing (P 0.625) each of the 6 cells (2 Â dose versus 3 Â antiretroviral therapyaviral Antioxidant regimen in men with HIVaAIDS M Batterham et al load strati®cation) were not signi®cantly different. Antiretroviral therapy predominantly included three (n 19) or four (n 12) agents. The type of regimens prescribed were similar in the two groups. Five men in each group were taking a regimen containing two nucleoside reverse transcriptase inhibitors (RTI) with one protease inhibitor (PI), three men in group one and four in group two took two RTIs with one non-nucleoside reverse transcriptase inhibitor (NRTI), two subjects in each group were taking two RTIs with one PI and one NRTI, three men in group one and one in group two were taking 2 RTIs with 2PIs, one man in each group was taking one RTI with one NRTI. Other regimens in group one included two RTI, two PI with one NRTI (n 1). Other regimens in group two included two RTIs (n 1), one RTI, one PI with one NRTI (n 2) and three PIs with one NRTI (n 1). Salvage regimens including the use of adjunctive therapy (Hydroxyurea) were used by two men in group two.
Compliance
Mean compliance assessed by pill count was high at 97.45 AE 5.66%. Mean compliance in group one was 99.19 AE 1.55% compared with 95.97 AE 7.33% in group two. The compliance of group one was signi®cantly higher than group two (P 0.015). There was no signi®-cance difference in compliance based on strati®cation group (P 0.832) or between those taking and those not taking antiretroviral therapy (P 0.554).
Baseline differences
Baseline differences between the three strati®ed groupings are outlined in Table 2 . The signi®cance of the difference between the three groups and also between those taking and those not taking antiretroviral therapy are presented for comparison. Uric acid levels were not signi®cantly different (P 0.387) at baseline between those taking didanosine (an antiretroviral medication; 441.6 AE 109.9 mmolal, n 8) and those not taking didanosine (383.8 AE 72.4 mmolal, n 40).
There was no signi®cant difference at baseline between the number of patients in the three strati®cation groups completing the study in groups one (n 22) and two (n 26) (P 0.643, w 2 ). There was no signi®cant difference between the pooled data for groups one and two at baseline for age, BMI, CD4 T-cell count, VL or dietary macronutrient intake (Pb0.05, data not shown). Serum glutathione peroxidase (GPX), allantoin, uric acid and the allantoinauric acid ratio were not signi®cantly different between those in group one and two (Pb0.05, data not shown). Baseline serum selenium (P 0.008) and glutathione (P 0.040) were higher and lipid peroxides signi®cantly lower (P 0.018) in those recruited into group two compared with group one.
Baseline correlations
Baseline viral load correlated negatively with baseline uric acid (r À0.3804, P 0.009), when a partial correlation was conducted to account for antiretroviral usage the relationship was attenuated to borderline signi®cance (r À0.2943, P 0.05). Uric acid did not correlate with CD4 count (r À0.131, P 0.428).
Viral load tended to correlate negatively with baseline GPX (r À0.2856, P 0 054). The relationship between baseline viral load and serum selenium (r À0.1336, P 0.376) and the relationship between baseline CD4 and serum selenium (r 0.1125, P 0.495) was not signi®cant.
Cholesterol and triglyceride levels were obtained from the medical records and readings were not always fasting. Change in oxidative stress parameters and viral load with supplementation Differences (P`0.05) existed between group one and two at baseline for serum selenium, GSH and LP0, therefore the baseline level was added as a covariate in the repeated measures ANOVA. The results of the repeated measures analysis are shown in Table 4 . The increases in serum selenium (P`0.001), glutathione (P`0.001) and glutathione peroxidase (P`0.001) over the treatment time were signi®cant, as was the decrease in lipid peroxides (P 0.028). Changes over the treatment time in serum allantoin (P 0.160), uric acid (P 0.635), the allantoinauric acid ratio (P 0.213) and HIV viral load (P 0.718) were not signi®cant. The main effect for group and treatment by time interactions were not signi®cant for any of the parameters measured (P ! 0.05), indicating the results for the two groups were not signi®cantly different.
Dietary intake
Dietary intake was assessed using the Foodworks V 2.0 software package (Xyris Software, Brisbane, Australia) by the same clinician (MB). Mean baseline dietary micronutrient intakes (zinc, magnesium, calcium, ribo¯avin, thiamin, iron, vitamin A, niacin and vitamin C) were above the recommended daily allowance for all nutrients measured (range 115 AE 34% for the RDA for zinc to 431 AE 373% of the RDA for vitamin C). There was no signi®cant difference at baseline in dietary micronutrient intake between those entering the two study groups (Pb0.05, data not shown). There was no signi®cant change in the intake of the measured macro or micronutrients over the study period, either in the absolute amount or the percentage of the RDA (Pb0.05, data not shown).
Discussion
The results of this study indicate that antioxidant supplementation signi®cantly increases antioxidant enzymatic defences as shown by the increases in selenium, glutathione and glutathione peroxidase. Antioxidant supplementation also signi®cantly decreased lipid peroxides. The effect of supplementation on allantoin, uric acid and the allantoin to uric acid ratio were not signi®cant. Antioxidant supplementation had no signi®cant effect on viral load. The main effect for group and the treatment by time interaction were not signi®cant for any of the parameters measured suggesting the effect of treatment was not different between the two doses of antioxidants used. These results suggest that there is no additional bene®t in terms of reduced oxidative damage with high doses of antioxidants. This ®nding is consistent with previous research showing that supplementation with high doses may not confer additional bene®t compared to low doses (Naidoo & Lux, 1998) .
Previous studies investigating the effects of prospective antioxidant supplementation on oxidative stress in HIV positive subjects are con¯icting. Delmas-Beauvieux et al (1996) supplemented HIV positive subjects with b-carotene, selenium or placebo for a 1 y period and demonstrated a signi®cant increase in glutathione peroxidase, although there was no signi®cant change in superoxide dismutase in the supplement groups vs placebo (Delmas-Beauvieux et al, 1996) . Look et al (1998) supplemented patients with selenium and N-acetylcysteine and were unable to demonstrate a signi®cant change in glutathione and glutathione peroxidase. Allard et al (1998a) compared the effects of vitamin E and C vs placebo in HIV-positive subjects and found that supplementation signi®cantly decreased lipid peroxidation compared with the placebo group. In addition the Vitamin E and C supplemented group had a reduction in viral load, approaching statistical signi®cance (P 0.10) when compared with the change in the placebo group. In contrast Look et al (1998) and Nimmagadda et al (1998) were Values log e transformed prior to analysis, viral load is log 10 transformed. *Indicates signi®cant differences between group one and two at baseline, therefore baseline values are added as a covariate in the repeated measures ANOVA. Unadjusted means are shown.
Antioxidant regimen in men with HIVaAIDS M Batterham et al unable to demonstrate signi®cant changes in viral load in their studies supplementing selenium in addition to NAC or b-carotene) respectively. In clinical practice we routinely recommended micronutrient supplementation to at least the RDA level in line with current recommendations (Coodley et al, 1993; Galvin, 1992) . In this study we aimed to determine if our clinical recommendations were of bene®t in reducing oxidative stress in our clients. The doses of vitamin C, E and b-carotene we were recommending were lower than those reported in the previous studies. We therefore wanted to test our current recommended intake and the intakes shown to have an effect in previous studies to determine their effect on oxidative stress and viral load. In a prior study the dose of 100 mg of selenium increased GPX (Delmas-Beauvieux et al, 1996) , in another study however, a dose of 500 mgaday did not result in a signi®cant change in GPX (Nimmagadda et al, 1998) . We were reluctant to trial a higher dose than 200 mg in view of the possible toxicity of this micronutrient at higher doses (Anonymous, 1984; Helzlsourer et al, 1985; Jensen et al, 1984; Yang et al, 1983) and current recommendations as to an upper intake of Se of 350 (Department of Health, 1991) to 450 mgaday (Abernathy et al, 1993; Poirer, (1994) . The high dose of vitamin C and E were chosen to determine if we could repeat the viral load reduction observed previously by Allard et al (1998a) who used doses of vitamin C and E of 1000 mgaday and 400 IUaday, respectively. As the BioACE Excell was a multimicronutrient preparation, the dose of the other nutrients was determined by the doses of C and E chosen. As there was a lack of published research on the use of coenzyme Q10 in HIV patients our standard dose of this antioxidant was guided by the clinical practice of our clients. The high dose was four times the standard dose in line with the increase in the multimicronutrient preparation. This dose of 200 mgaday of coenzyme 010 has previously been shown to be well tolerated in patients with non-insulin dependent diabetes mellitus (Eriksson et al, 1999) .
Serum selenium de®ciency is a strong predictor of mortality in people with HIVaAIDS (Baum et al, 1997) and serum selenium levels have previously been shown to correlate positively with CD4 T-cell count (Look et al, 1997) . There was no signi®cant correlation at baseline between CD4 T-cell count or viral load with serum selenium in the present study.
Previously high uric acid levels have been shown to be associated with low CD4 counts and disease progression (Manfredi et al, 1996; Manfredi & Chiodo, 1998) . Interestingly the present study did show a strong negative relationship between uric acid and viral load; to our knowledge this has not previously been reported. This relationship was attenuated by accounting for antiretroviral usage; nevertheless, the relationship remained of borderline signi®cance (P 0.05) and is worthy of further investigation. Uric acid is the most abundant water soluble antioxidant in serum, being on average 5 ± 10 times the concentration of ascorbic acid.
Uric acid is an end product of metabolism of the antiretroviral therapy didanosine and elevated levels of uric acid have been reported in HIV-positive patients taking this antiretroviral medication (Richardson et al, 1993) . Manfredi et al (1996) ), however, report that didanosine use did not result in increased uric acid levels, nor did the use of zidovudine, zalcitabine or stavudine. One report assessing uric acid levels in patients taking Indinavir showed no abnormalities (Reiter et al, 1999) .
Use of the thiobarbituic acid reagent test to determine lipid peroxides has been criticised as a marker of oxidative stress for two reasons. Firstly other malondialdehyde adducts may be detected, this is overcome in the present study by the use of HPLC to separate the speci®c adduct of interest (Halliwell & Chirico, 1993) . Secondly lipid peroxides are only one product of oxidative damage; other markers indicating DNA and protein oxidative damage may be more useful (Halliwell & Chirico, 1993) . Lipid peroxides have been shown to correlate with LDL cholesterol and triglycerides (Bonithon-Kopp et al, 1997). There was no correlation between lipid peroxides and total cholesterol or triglycerides in the present study, although values were obtained from the medical records and were not necessarily fasting readings. The high prevalence of hyperlipidaemia in HIV positive populations, particularly those on highly active antiretroviral therapy (Carr et al, 1998) , may result in a reduced ef®cacy of this test in this population.
Allantoin, uric acid and the allantoin to uric acid ratio did not change signi®cantly in this study. Allantoin levels were normal in all patients except one at baseline (data not shown); this test may not be a sensitive enough marker of oxidative damage for use in this population. Although an increase in uric acid is reported only in patients on didanosine (an antiretroviral agent), uric acid was signi®cantly higher in those on antiretroviral therapy (Table 2) in this study and it is dif®cult to exclude the possibility that antiretroviral usage may be affecting the results.
Reduced glutathione only was measured in this study. Measuring the reduced glutathione to oxidized glutathione ratio may give a more complete picture of the relationship between the substrate and the end products of this reaction (Aukrust & Mu Èller, 1999) .
Therefore, while the measures of antioxidant defence in this study (selenium, glutathione and glutathione peroxidase) changed signi®cantly with supplementation, the measures of oxidative stress used may not be adequate to detect changes. Use of lipid peroxides may be limited by the advanced nature of the oxidative process by the time changes in this parameter are detected and by the possible in¯uence of hyperlipidaemia. Allantoin and uric acid measurement in this study was either not sensitive enough to detect changes or low levels of oxidative stress at baseline meant changes in this parameter were unlikely. Future studies should investigate the use of other measures of oxidative stress.
This study was conducted in an outpatient setting without a laboratory on the premises. This limited the types of serum analysis able to be conducted as serum could not be Antioxidant regimen in men with HIVaAIDS M Batterham et al prepared or analysed on site. This prevented measures of other serum micronutrients which would have allowed assessment of the relationship between baseline dietary intake and serum parameters. It should also be noted that the baseline CD4 count and viral load in the group studied suggest moderate disease severity and different results may have been obtained in a group of HIV-positive patients with more advanced disease.
Despite strati®cation on entry to attempt to limit confounding baseline variables, signi®cant baseline difference in antioxidant defences and oxidative stress existed between the two arms of this study. This may have compromised the dose ranging component of the study. Nevertheless signi®-cant changes over time on treatment were obtained in the repeated measures analysis, suggesting the lower dose would be adequate for future studies. Future research may consider stratifying on entry on baseline antioxidant status.
Conclusions
Antioxidant supplementation was able to improve markers of antioxidant defence and oxidative stress. A high-dose supplement was not necessary to induce change. Antioxidant supplementation did not have an effect on viral load. Future studies should incorporate a variety of oxidative stress markers and perhaps stratify prior to study entry based on their existing antioxidantaROS system.
